Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    January 2025
  1. VAN AS N, Patel J, Hall E
    Stereotactic Body Radiotherapy in Localized Prostate Cancer. Reply.
    N Engl J Med. 2025;392:206-207.
    PubMed    


  2. KASHIHARA T
    Stereotactic Body Radiotherapy in Localized Prostate Cancer.
    N Engl J Med. 2025;392:206.
    PubMed    


    December 2024
  3. HUGOSSON J, Godtman RA, Stranne J
    Four Years of Screening for Prostate Cancer with PSA and MRI. Reply.
    N Engl J Med. 2024;391:2274.
    PubMed    


  4. TILKI D, Chen MH, D'Amico AV
    Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:2273-2274.
    PubMed    


    October 2024
  5. VAN AS N, Griffin C, Tree A, Patel J, et al
    Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.
    N Engl J Med. 2024;391:1413-1425.
    PubMed     Abstract available


  6. HOLMBERG L, Garmo H, Andersson SO, Andren O, et al
    Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer.
    N Engl J Med. 2024;391:1362-1364.
    PubMed    


    September 2024
  7. PINSKY PF
    Prostate Biopsy in Men with an Elevated PSA Level - Reducing Overdiagnosis.
    N Engl J Med. 2024;391:1153-1154.
    PubMed    


  8. HUGOSSON J, Godtman RA, Wallstrom J, Axcrona U, et al
    Results after Four Years of Screening for Prostate Cancer with PSA and MRI.
    N Engl J Med. 2024;391:1083-1095.
    PubMed     Abstract available


  9. GANGULI I
    How Does Health Care Burden Patients? Let Me Count the Days.
    N Engl J Med. 2024;391:880-883.
    PubMed    


    August 2024
  10. ARENAS-GALLO C, Michie M, Jones N, Pronovost PJ, et al
    Race-Based Screening under the Public Health Ethics Microscope - The Case of Prostate Cancer.
    N Engl J Med. 2024;391:468-474.
    PubMed    


    January 2024
  11. SHORE ND, Tarazi J, Freedland SJ
    Enzalutamide in Biochemically Recurrent Prostate Cancer. Reply.
    N Engl J Med. 2024;390:90-91.
    PubMed    


  12. POLLAK M
    Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2024;390:90.
    PubMed    


    October 2023
  13. APARICIO A
    Biochemical Recurrence in Prostate Cancer - Tilting the Scale.
    N Engl J Med. 2023;389:1522-1523.
    PubMed    


  14. FREEDLAND SJ, de Almeida Luz M, De Giorgi U, Gleave M, et al
    Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
    N Engl J Med. 2023;389:1453-1465.
    PubMed     Abstract available


  15. NADAMUNI M, D'Amico AV, Donovan JL, Hamdy FC, et al
    Decision Making in Prostate Cancer.
    N Engl J Med. 2023;389:1335-1338.
    PubMed    


    July 2023
  16. PINSKY PF, Parnes H
    Screening for Prostate Cancer. Reply.
    N Engl J Med. 2023;389:94.
    PubMed    


  17. PRESTI J JR, Alexeeff S, Avins AL
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:93-94.
    PubMed    


  18. INAMURA K
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:93.
    PubMed    


  19. HOOVER J, Butterfass C, Ponder A
    Screening for Prostate Cancer.
    N Engl J Med. 2023;389:92-93.
    PubMed    


  20. HAMDY FC, Donovan JL
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer. Reply.
    N Engl J Med. 2023;389:92.
    PubMed    


  21. DAVIS MJ, Stephens A, Abdollah F
    Fifteen-Year Outcomes of the ProtecT Trial for Localized Prostate Cancer.
    N Engl J Med. 2023;389:90-92.
    PubMed    


    June 2023

  22. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023;388:2208.
    PubMed    


    April 2023

  23. Waiting on Prostate Cancer.
    N Engl J Med. 2023;388:e54.
    PubMed    


  24. PINSKY PF, Parnes H
    Screening for Prostate Cancer.
    N Engl J Med. 2023;388:1405-1414.
    PubMed    


    March 2023
  25. SARTOR O
    Localized Prostate Cancer - Then and Now.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMe2300807.
    PubMed    


  26. HAMDY FC, Donovan JL, Lane JA, Metcalfe C, et al
    Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.
    N Engl J Med. 2023 Mar 11. doi: 10.1056/NEJMoa2214122.
    PubMed     Abstract available


    February 2023
  27. FIZAZI K, Piulats JM, Reaume MN, Ostler P, et al
    Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
    N Engl J Med. 2023 Feb 16. doi: 10.1056/NEJMoa2214676.
    PubMed     Abstract available


  28. GAGLIANO-JUCA T, Hirsch MS, McGregor BA, Basaria S, et al
    Failure of Androgen-Deprivation Therapy Due to Ectopic hCG Secretion.
    N Engl J Med. 2023;388:660-662.
    PubMed    


    December 2022
  29. GULATI R
    Reducing Prostate Cancer Overdiagnosis.
    N Engl J Med. 2022;387:2187-2188.
    PubMed    


  30. HUGOSSON J, Mansson M, Wallstrom J, Axcrona U, et al
    Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only.
    N Engl J Med. 2022;387:2126-2137.
    PubMed     Abstract available


    September 2022

  31. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
    N Engl J Med. 2022;387:860.
    PubMed    


    June 2022
  32. SMITH MR
    Darolutamide in Metastatic Prostate Cancer. Reply.
    N Engl J Med. 2022;386:2345.
    PubMed    


  33. BOWLING GC, Dimitrakoff JD
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    


  34. TURCO F, Tucci M, Buttigliero C
    Darolutamide in Metastatic Prostate Cancer.
    N Engl J Med. 2022;386:2344.
    PubMed    


    February 2022
  35. SMITH MR, Hussain M, Saad F, Fizazi K, et al
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    N Engl J Med. 2022 Feb 17. doi: 10.1056/NEJMoa2119115.
    PubMed     Abstract available


    December 2021
  36. SARTOR O, Morris MJ, Kraus BJ
    Lutetium-177-PSMA-617 for Prostate Cancer. Reply.
    N Engl J Med. 2021;385:2495-2496.
    PubMed    


  37. DALLA VOLTA A, Grisanti S, Berruti A
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2495.
    PubMed    


  38. KASHIHARA T, Kashihara K
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494-2495.
    PubMed    


  39. HINDIE E
    Lutetium-177-PSMA-617 for Prostate Cancer.
    N Engl J Med. 2021;385:2494.
    PubMed    


    November 2021
  40. EKLUND M, Discacciati A, Nordstrom T
    MRI-Targeted Biopsy in Prostate Cancer Screening. Reply.
    N Engl J Med. 2021;385:2110-2111.
    PubMed    


  41. YOSHIDA S, Fujii Y
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2110.
    PubMed    


  42. AL HUSSEIN AL AWAMLH B, Spratt DE, Shoag JE
    MRI-Targeted Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021;385:2109-2110.
    PubMed    


    July 2021
  43. EKLUND M, Jaderling F, Discacciati A, Bergman M, et al
    MRI-Targeted or Standard Biopsy in Prostate Cancer Screening.
    N Engl J Med. 2021 Jul 9. doi: 10.1056/NEJMoa2100852.
    PubMed     Abstract available


    June 2021
  44. SARTOR O, de Bono J, Chi KN, Fizazi K, et al
    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
    N Engl J Med. 2021 Jun 23. doi: 10.1056/NEJMoa2107322.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.